Alpha-Galactosidase A Replacement Therapy for Fabry Disease

NCT00048906 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

NIH

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: DRX005B

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)